Monitor upcoming topline data for brepocitinib in non-infectious uveitis (NIU) and cutaneous sarcoidosis (CS) in the second half of 2026, which could validate the JAK1/TYK2 platform. The batoclimab TED failure increases focus on IMVT-1402 as Immunovant's lead asset.
Price Chart
Executive Summary
Roivant reported preliminary cash of $4.3B as of March 31, 2026, and announced a new Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), expanding its late-stage pipeline. However, Immunovant's Phase 3 trials for batoclimab in thyroid eye disease failed to meet primary endpoints, representing a clinical setback.
Key Financial Metrics
Key Facts
- Preliminary cash, cash equivalents, and marketable securities totaled $4.3 billion as of March 31, 2026
- New seamless Phase 2b/3 potentially registrational trial for brepocitinib in lichen planopilaris (LPP) initiated, marking the fourth indication in its development program
- Immunovant's two Phase 3 trials for batoclimab in thyroid eye disease (TED) failed to meet the primary endpoint of 2mm proptosis responder rate at Week 24
- Company repurchased 3.96 million shares for $109.7 million during the quarter
Financial Impact
Cash position remains strong at $4.3B, supporting operations into profitability; $109.7M in share repurchases executed
Risk Factors
- Clinical failure of batoclimab in TED represents a significant pipeline setback and potential loss of partnership value with HanAll
- Dilution risk from future capital raises remains elevated despite strong cash balance, given the company's history of equity financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-012885 |
| Document: ef20069685_ex99-1.htm | 0001140361-26-012885 |
| Document: 0001140361-26-012885-index-headers.html | 0001140361-26-012885 |
| Document: 0001140361-26-012885-index.html | 0001140361-26-012885 |
| Document: 0001140361-26-012885.txt | 0001140361-26-012885 |
| 8-K Data (Synthetic) | 0001140361-26-012885 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $36.80 | awaiting T+20 | — | $36.71 (−0.24%) |
Oct 5, 2026 21d ago | Insider Cluster | $35.53 | awaiting T+20 | — | $36.71 (−3.32%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.71 (−7.69%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.71 (−7.69%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.71 (−7.69%) |
Sep 1, 2026 7w ago | Insider Cluster | $34.18 $36.57 | ▲ +6.99% | ▲ +7.32% | $36.71 (+7.40%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.71 (−2.32%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.71 (−2.32%) |
Aug 26, 2026 8w ago | Press Release | $36.75 $38.99 | ▲ +6.10% | ▲ +4.89% | $36.71 (−0.11%) |
Aug 6, 2026 11w ago | 8-K | $35.12 $34.41 | ▼ −2.02% | ▼ −2.62% | $36.71 (+4.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers